Neoadjuvant Trial of Lapatinib for the Treatment of Women With DCIS Breast Cancer
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Lapatinib (Primary)
- Indications Breast cancer; Ductal carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms LAPIS
- 05 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Apr 2014 Planned number of patients changed from 120 to 60, as per ClinicalTrials.gov record.